Home Stocks Syngene International Ltd

Syngene International Ltd

The live share price of Syngene International Ltd (SYNGENE) as on 03 Oct 9:59am is ₹810.65 from NSE/BSE.

SYNGENE NSE

₹810.65 ▲0.81% (6.5)

As on Oct 03, 2023 03:29 PM IST

How do you feel today about Syngene International Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

64.26

PB Ratio

8.59

Dividend Yield

0.16%

Sector PB

4.66

Sector PE

39.72

Sector Div Yld

0.78%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Life Sciences Tools & Services

Market Cap

Midcap, ₹31,087 Cr

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

The following charts display the financial performance of the Syngene International Ltd (SYNGENE) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Syngene International Ltd (SYNGENE), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Life Sciences Tools & Services

Market Cap

Midcap, ₹31,087 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	3,263 Cr	+20.36%
Operating Expense	248 Cr	+22.81%
Net Income	464 Cr	+17.33%
Net Profit Margin	14.23%	-2.53%
Earning Per Share	11	+17.15%
EBITDA	1,005 Cr	+22.87%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	1,356 Cr	+5.8%
Total Assets	5,831 Cr	+4.8%
Total Liabilities	2,213 Cr	-2.35%
Total Equity	3,618 Cr	+9.72%
Shares Outstanding	40.14 Cr	+0.15%
Price to Book	6.6	-9.09%
Return on Assets	8.15%	+7.52%
Return on Capital	17.66 Cr	+14.53%

Cash Flows

(INR)		Y/Y Change
Net Income	464 Cr	+17.33%
Cash from Operations	823 Cr	+41.84%
Cash from Investing	-653 Cr	+6.96%
Cash from Financing	-342 Cr	+994.25%
Net Change in Cash	-172 Cr	+180.16%
Free Cash Flow	305 Cr	+190.39%

Shareholding Pattern

Total Promoter Holding

54.8%

Unpledged

Foreign Institutions

23.19%

Foreign Institutions

Retail & Others

10.81%

Retail & Others

Other Parties

Other Domestic Institutions

2.63%

Insurance Firms

Others

Mutual Funds

8.58%

Mutual Funds

Peers

DIVISLAB

Divi's Laboratories Ltd

PE Ratio

65.86

1Y Return

▲1.03%

AARTIPHARM

Aarti Pharmalabs Ltd

PE Ratio

21.62

1Y Return

▲60.26%

DCAL

Dishman Carbogen Amcis Ltd

PE Ratio

-150.3

1Y Return

▲76.78%

VIMTALABS

Vimta Labs Ltd

PE Ratio

26.01

1Y Return

▲70.49%

Latest News

Biocon names Peter Bains as group CEO, will report to Kiran Mazumdar-Shaw

2 weeks ago on Business Today

Change since news ▲2.86%

‘Peter has a comprehensive understanding of the Biocon Group, having led Syngene for 5 years, taking it through its very successful IPO in 2015,’ says Mazumdar-Shaw

Laurus Labs, Syngene, Ipca, Gland Pharma Report Export Growth In August

2 weeks ago on Bloomberg Quint

Change since news ▲2.86%

Exports were down for Divi’s Laboratories Ltd. and Suven Pharmaceuticals Ltd., said JM Financial.

Laurus Labs sinks 6% after Kotak Institutional Equities downgrades rating to ‘sell’

3 weeks ago on Moneycontrol

Change since news ▲3.32%

Laurus Labs’ Synthesis segment is currently trading at a premium of more than 25 percent higher than Syngene. Considering the significant differences in their capabilities and size, the brokerage firm finds it hard to justify this premium.

FAQs on Syngene International Ltd

How to buy Syngene International Ltd stocks?

You can easily buy the stocks/shares of Syngene International Ltd (SYNGENE) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Syngene International Ltd?

The stock price of Syngene International Ltd as on 03 Oct 2023 is ₹810.65

What is the 52-week High and Low of Syngene International Ltd?

The 52-week high and low of Syngene International Ltd (SYNGENE) is ₹860.25 and ₹535.1.

What is the PE and PB ratio of Syngene International Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Syngene International Ltd are 64.26 and 8.59 respectively.

What are the peers or stocks similar to Syngene International Ltd?

The peers or stocks similar to Syngene International Ltd are Divi's Laboratories Ltd, Aarti Pharmalabs Ltd, Dishman Carbogen Amcis Ltd, Vimta Labs Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Syngene International Ltd belong to?

Syngene International Ltd (SYNGENE) belongs to the Labs & Life Sciences Services sector.

What is the Market Cap of Syngene International Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syngene International Ltd (SYNGENE) is ₹31,087 Cr as of 03 Oct 2023

Can't decide whether or not to buy Syngene International Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.